Stocks · News reference
Adagene Inc. has initiated dosing for the first patient in a Phase 1 clinical trial evaluating the combination of its antibody muzastotug with Incyte's bispecific antibody INCA33890 for treating microsatellite stable colorectal cancer.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Adagene Inc. announced that its senior management will participate in a fireside chat and one-on-one meetings at the upcoming Guggenheim Securities 3rd Annual Healthcare Innovation Conference.
HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $7 price target.
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio,
Chardan Capital analyst Gautam Chukka initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.10) by 100 percent. This is a 5.26 percent decrease over losses of $(0.19) per share from the same